1
|
Wen J, Guan Z, Yu B, Guo J, Shi Y, Hu L. Circular RNA hsa_circ_0076906 competes with OGN for miR-1305 biding site to alleviate the progression of osteoporosis. Int J Biochem Cell Biol 2020; 122:105719. [PMID: 32087327 DOI: 10.1016/j.biocel.2020.105719] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2019] [Revised: 02/11/2020] [Accepted: 02/19/2020] [Indexed: 12/11/2022]
Abstract
Osteoporosis is a skeletal disorder, the pathogenic factors of which include the decreased ability of osteogenesis and enhanced osteolysis. Human-derived mesenchymal stem cells (hMSCs) possess the differential capacity to osteoblasts and chondrocytes, so the application of hMSCs in bone tissue is promising to be effective. A group of RNAs which lack of 5' and 3'ends called circular RNAs (circRNAs) were discovered. In this study, we described a previously found circular RNA, circ_0076906, to bind miR-1305 and regulate its target gene, Osteoglycin (OGN), thus regulate osteogenic differentiation of hMSCs and alleviate the progression of osteoporosis. Osteogenic differentiation induced in hMSCs; qRT-PCR and western blot to examine the expressions of mRNAs and proteins; Alkaline phosphatase activity and Alizarin red staining to examine bone formation; luciferase report experiments to detect the interaction between molecules; and the nuclear/cytoplasm separation of cells. 1. Circ_0076906 was induced in osteogenic differentiation; 2. Circ_0076906 silencing inhibited osteogenesis-related genes in hMSCs; 3. Circ_0076906 acted as a sponge for miR-1305; 4. MiR-1305 regulated OGN expression; 5. Circ_0076906 induced-osteogenic differentiation depended on miR-1305/ OGN pathway. Circ_0076906 relieved osteoporosis and promoted osteogenic differentiation through the miR-1305/ OGN pathway.
Collapse
Affiliation(s)
- Jian Wen
- Department of Spinal Surgery, Peking University Shenzhen Hospital, Lianhua Road, Shenzhen, 518000 Guangdong, China.
| | - Zhiping Guan
- Department of Spinal Surgery, Peking University Shenzhen Hospital, Lianhua Road, Shenzhen, 518000 Guangdong, China
| | - Binsheng Yu
- Department of Spinal Surgery, Peking University Shenzhen Hospital, Lianhua Road, Shenzhen, 518000 Guangdong, China
| | - Jing Guo
- Department of Spinal Surgery, Peking University Shenzhen Hospital, Lianhua Road, Shenzhen, 518000 Guangdong, China
| | - Yan Shi
- Department of Spinal Surgery, Peking University Shenzhen Hospital, Lianhua Road, Shenzhen, 518000 Guangdong, China
| | - Lisheng Hu
- Department of Spinal Surgery, Peking University Shenzhen Hospital, Lianhua Road, Shenzhen, 518000 Guangdong, China
| |
Collapse
|
2
|
Chen R, Qiu H, Tong Y, Liao F, Hu X, Qiu Y, Liao Y. MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs. Biochem Biophys Res Commun 2019; 516:666-672. [PMID: 31248594 DOI: 10.1016/j.bbrc.2019.06.083] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 06/16/2019] [Indexed: 01/08/2023]
Abstract
To clarify the function of microRNA-19a-3p (miRNA-19a-3p) in the osteogenic differentiation of human-derived mesenchymal stem cells (hMSCs) and the potential mechanism. Serum levels of miRNA-19a-3p, RUNX2 and OCN in osteoporosis patients and controls were determined by quantitative real-time polymerase chain reaction (qRT-PCR). Alkaline phosphatase (ALP) content and calcification ability during the process of osteogenic differentiation were examined by ALP staining and alizarin red staining, respectively. After altering miRNA-19a-3p level by transfection of miRNA-19a-3p mimic or inhibitor, we detected relative levels of miRNA-19a-3p, RUNX2 and OCN in hMSCs by qRT-PCR. The binding relationship between miRNA-19a-3p and HDAC4 was predicted by TargetScan and further verified by dual-luciferase reporter gene assay. Relative expression of HDAC4 was detected by Western blot and qRT-PCR in hMSCs transfected with miRNA-19a-3p mimic or inhibitor. Regulatory effects of miRNA-19a-3p/HDAC4 axis on osteogenic differentiation of hMSCs were evaluated. MiRNA-19a-3p was downregulated in osteoporosis patients. Its level gradually increased in hMSCs with the prolongation of osteogenic differentiation. Overexpression of miRNA-19a-3p upregulated levels of RUNX2 and OCN, and enhanced ALP activity. Knockdown of miRNA-19a-3p obtained the opposite trends. Dual-luciferase reporter gene assay verified that miRNA-19a-3p could target to 3'UTR of HDAC4. Protein level of HDAC4 was negatively regulated by miRNA-19a-3p in hMSCs. More importantly, co-overexpression of miRNA-19a-3p and HDAC4 could reverse the regulatory effects of miRNA-19a-3p on enhancing ALP activity and upregulating RUNX2 and OCN. MiRNA-19a-3p promotes the osteogenic differentiation of hMSCs by inhibiting HDAC4 expression, thus alleviating the progression of osteoporosis.
Collapse
Affiliation(s)
- Rijiang Chen
- Department of Orthopaedics, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China
| | - Hanmin Qiu
- Department of Orthopaedics, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China
| | - Yan Tong
- Department of Endocrine, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China
| | - Fake Liao
- Department of Orthopaedics, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China
| | - Xiunian Hu
- Department of Orthopaedics, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China
| | - Yongrong Qiu
- Department of Orthopaedics, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China
| | - Yuanjun Liao
- Department of Orthopaedics, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China.
| |
Collapse
|
3
|
OVOL1 Influences the Determination and Expansion of iPSC Reprogramming Intermediates. Stem Cell Reports 2019; 12:319-332. [PMID: 30639212 PMCID: PMC6372973 DOI: 10.1016/j.stemcr.2018.12.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Revised: 12/11/2018] [Accepted: 12/12/2018] [Indexed: 01/24/2023] Open
Abstract
During somatic cell reprogramming to induced pluripotent stem cells (iPSCs), fibroblasts undergo dynamic molecular changes, including a mesenchymal-to-epithelial transition (MET) and gain of pluripotency; processes that are influenced by Yamanaka factor stoichiometry. For example, in early reprogramming, high KLF4 levels are correlated with the induction of functionally undefined, transiently expressed MET genes. Here, we identified the cell-surface protein TROP2 as a marker for cells with transient MET induction in the high-KLF4 condition. We observed the emergence of cells expressing the pluripotency marker SSEA-1+ mainly from within the TROP2+ fraction. Using TROP2 as a marker in CRISPR/Cas9-mediated candidate screening of MET genes, we identified the transcription factor OVOL1 as a potential regulator of an alternative epithelial cell fate characterized by the expression of non-iPSC MET genes and low cell proliferation. Our study sheds light on how reprogramming factor stoichiometry alters the spectrum of intermediate cell fates, ultimately influencing reprogramming outcomes. High KLF4 activates transient MET genes early in reprogramming The cell-surface protein TROP2 marks a transient epithelial population TROP2 is followed by SSEA-1 presentation in cells efficient at reprogramming Suppression of partially reprogrammed cells improves the purity of reprogramming
Collapse
|
4
|
Guo G, von Meyenn F, Rostovskaya M, Clarke J, Dietmann S, Baker D, Sahakyan A, Myers S, Bertone P, Reik W, Plath K, Smith A. Epigenetic resetting of human pluripotency. Development 2017; 144:2748-2763. [PMID: 28765214 PMCID: PMC5560041 DOI: 10.1242/dev.146811] [Citation(s) in RCA: 186] [Impact Index Per Article: 26.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2016] [Accepted: 06/09/2017] [Indexed: 12/12/2022]
Abstract
Much attention has focussed on the conversion of human pluripotent stem cells (PSCs) to a more naïve developmental status. Here we provide a method for resetting via transient histone deacetylase inhibition. The protocol is effective across multiple PSC lines and can proceed without karyotype change. Reset cells can be expanded without feeders with a doubling time of around 24 h. WNT inhibition stabilises the resetting process. The transcriptome of reset cells diverges markedly from that of primed PSCs and shares features with human inner cell mass (ICM). Reset cells activate expression of primate-specific transposable elements. DNA methylation is globally reduced to a level equivalent to that in the ICM and is non-random, with gain of methylation at specific loci. Methylation imprints are mostly lost, however. Reset cells can be re-primed to undergo tri-lineage differentiation and germline specification. In female reset cells, appearance of biallelic X-linked gene transcription indicates reactivation of the silenced X chromosome. On reconversion to primed status, XIST-induced silencing restores monoallelic gene expression. The facile and robust conversion routine with accompanying data resources will enable widespread utilisation, interrogation, and refinement of candidate naïve cells.
Collapse
Affiliation(s)
- Ge Guo
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
| | | | - Maria Rostovskaya
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
| | - James Clarke
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
| | - Sabine Dietmann
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
| | - Duncan Baker
- Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN, UK
| | - Anna Sahakyan
- Department of Biological Chemistry, University of California, Los Angeles, CA 90095, USA
- Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
| | - Samuel Myers
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
| | - Paul Bertone
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
| | - Wolf Reik
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
- Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK
- Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
| | - Kathrin Plath
- Department of Biological Chemistry, University of California, Los Angeles, CA 90095, USA
- Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
| | - Austin Smith
- Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK
- Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, UK
| |
Collapse
|
5
|
Hirabayashi J, Tateno H, Onuma Y, Ito Y. A Novel Probe as Surface Glycan Marker of Pluripotent Stem Cells: Research Outcomes and Application to Regenerative Medicine. Adv Healthc Mater 2015; 4:2520-9. [PMID: 25872477 DOI: 10.1002/adhm.201400837] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Revised: 02/25/2015] [Indexed: 12/21/2022]
Abstract
Human pluripotent stem cells (hPSCs), represented by embryonic stem (hESCs) and induced pluripotent stem cells (hiPSCs), are attracting increasing attention in various research fields. However, their application in a clinical scenario must overcome an important hurdle given that these cells are potentially tumorigenic. This inherent problem becomes more significant as the number of transplanted cells becomes larger. In this Progress Report, recent findings concerning a novel glycan marker for hPSCs are described, as well as attempts made in relation to its practical application to regenerative medicine. In line with current thinking in the glycoscience field, it is assumed that cellular glycomes are closely related to cell functions. Based on this premise, hESCs and hiPSCs are analyzed by an advanced glycan profiling technology--the high-density lectin microarray. It is found that all human iPSCs derived from different tissular origins show essentially the same glycan profiles, which are typified by several characteristic structural features. In addition, a recombinant lectin probe, rBC2LCN, which shows rigorous specificity to H type 1 and 3 glycan structures, is found to serve as an excellent probe for hPSCs.
Collapse
Affiliation(s)
- Jun Hirabayashi
- Research Center for Stem Cell Engineering; National Institute of Advanced Industrial Science and Technology; Central-2, 1-1-1, Umezono Tsukuba Ibaraki 305-8568 Japan
| | - Hiroaki Tateno
- Research Center for Stem Cell Engineering; National Institute of Advanced Industrial Science and Technology; Central-2, 1-1-1, Umezono Tsukuba Ibaraki 305-8568 Japan
| | - Yasuko Onuma
- Research Center for Stem Cell Engineering; National Institute of Advanced Industrial Science and Technology; Central-2, 1-1-1, Umezono Tsukuba Ibaraki 305-8568 Japan
| | - Yuzuru Ito
- Research Center for Stem Cell Engineering; National Institute of Advanced Industrial Science and Technology; Central-2, 1-1-1, Umezono Tsukuba Ibaraki 305-8568 Japan
| |
Collapse
|
6
|
Shao J, Zhang W, Yang T. Using mesenchymal stem cells as a therapy for bone regeneration and repairing. Biol Res 2015; 48:62. [PMID: 26530042 PMCID: PMC4630918 DOI: 10.1186/s40659-015-0053-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 10/22/2015] [Indexed: 02/07/2023] Open
Abstract
Bone is a unique tissue which could regenerate completely after injury rather than heal itself with a scar. Compared with other tissues the difference is that, during bone repairing and regeneration, after the inflammatory phase the mesenchymal stem cells (MSCs) are recruited to the injury site and differentiate into either chondroblasts or osteoblasts precursors, leading to bone repairing and regeneration. Besides these two precursors, the MSCs can also differentiate into adipocyte precursors, skeletal muscle precursors and some other mesodermal cells. With this multilineage potentiality, the MSCs are probably used to cure bone injury and other woundings in the near future. Here we will introduce the recent developments in understanding the mechanism of MSCs action in bone regeneration and repairing.
Collapse
Affiliation(s)
- Jin Shao
- Department of Orthopaedics, Shanghai Pudong New Area Gongli Hospital, Second Military Medical University, Shanghai, 200135, China.
| | - Weiwei Zhang
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
| | - Tieyi Yang
- Department of Orthopaedics, Shanghai Pudong New Area Gongli Hospital, Second Military Medical University, Shanghai, 200135, China.
| |
Collapse
|
7
|
Matsumoto S, Nakao H, Kawabe K, Nonaka M, Toyoda H, Takishima Y, Kawabata K, Yamaguchi T, Furue MK, Taki T, Okumura T, Yamazaki Y, Nakaya S, Kawasaki N, Kawasaki T. A Cytotoxic Antibody Recognizing Lacto-N-fucopentaose I (LNFP I) on Human Induced Pluripotent Stem (hiPS) Cells. J Biol Chem 2015; 290:20071-85. [PMID: 26100630 DOI: 10.1074/jbc.m115.657692] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Indexed: 01/26/2023] Open
Abstract
We have generated a mouse monoclonal antibody (R-17F, IgG1 subtype) specific to human induced pluripotent stem (hiPS)/embryonic stem (ES) cells by using a hiPS cell line as an antigen. Triple-color confocal immunostaining images of hiPS cells with R-17F indicated that the R-17F epitope was expressed exclusively and intensively on the cell membranes of hiPS cells and co-localized partially with those of SSEA-4 and SSEA-3. Lines of evidence suggested that the predominant part of the R-17F epitope was a glycolipid. Upon TLC blot of total lipid extracts from hiPS cells with R-17F, one major R-17F-positive band was observed at a slow migration position close to that of anti-blood group H1(O) antigen. MALDI-TOF-MS and MS(n) analyses of the purified antigen indicated that the presumptive structure of the R-17F antigen was Fuc-Hex-HexNAc-Hex-Hex-Cer. Glycan microarray analysis involving 13 different synthetic oligosaccharides indicated that R-17F bound selectively to LNFP I (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc). A critical role of the terminal Fucα1-2 residue was confirmed by the selective disappearance of R-17F binding to the purified antigen upon α1-2 fucosidase digestion. Most interestingly, R-17F, when added to hiPS/ES cell suspensions, exhibited potent dose-dependent cytotoxicity. The cytotoxic effect was augmented markedly upon the addition of the secondary antibody (goat anti-mouse IgG1 antibody). R-17F may be beneficial for safer regenerative medicine by eliminating residual undifferentiated hiPS cells in hiPS-derived regenerative tissues, which are considered to be a strong risk factor for carcinogenesis.
Collapse
Affiliation(s)
- Shogo Matsumoto
- From the Research Center for Glycobiotechnology, Ritsumeikan University, Noji-Higashi, 1-1-1, Kusatsu, Shiga 525-8577, Japan
| | - Hiromi Nakao
- From the Research Center for Glycobiotechnology, Ritsumeikan University, Noji-Higashi, 1-1-1, Kusatsu, Shiga 525-8577, Japan
| | - Keiko Kawabe
- From the Research Center for Glycobiotechnology, Ritsumeikan University, Noji-Higashi, 1-1-1, Kusatsu, Shiga 525-8577, Japan, the Laboratory of Stem Cell Cultures and
| | - Motohiro Nonaka
- From the Research Center for Glycobiotechnology, Ritsumeikan University, Noji-Higashi, 1-1-1, Kusatsu, Shiga 525-8577, Japan
| | - Hidenao Toyoda
- the Laboratory of Bio-analytical Chemistry, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga 525-8577, Japan
| | - Yuto Takishima
- the Laboratory of Bio-analytical Chemistry, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga 525-8577, Japan
| | - Kenji Kawabata
- the Laboratory of Stem Cell Regulation, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan
| | - Tomoko Yamaguchi
- the Laboratory of Stem Cell Regulation, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan
| | | | - Takao Taki
- the Niigata University of Pharmacy and Applied Life Sciences, Niigata 956-0841, Japan, AGT&T Co. Ltd., Tokushima 771-1151, Japan, and
| | - Takeshi Okumura
- the Analytical and Measuring Instruments Division, Shimadzu Corp., Kyoto 604-8511, Japan
| | - Yuzo Yamazaki
- the Analytical and Measuring Instruments Division, Shimadzu Corp., Kyoto 604-8511, Japan
| | - Shuuichi Nakaya
- the Analytical and Measuring Instruments Division, Shimadzu Corp., Kyoto 604-8511, Japan
| | - Nobuko Kawasaki
- From the Research Center for Glycobiotechnology, Ritsumeikan University, Noji-Higashi, 1-1-1, Kusatsu, Shiga 525-8577, Japan
| | - Toshisuke Kawasaki
- From the Research Center for Glycobiotechnology, Ritsumeikan University, Noji-Higashi, 1-1-1, Kusatsu, Shiga 525-8577, Japan,
| |
Collapse
|
8
|
Tateno H, Matsushima A, Hiemori K, Onuma Y, Ito Y, Hasehira K, Nishimura K, Ohtaka M, Takayasu S, Nakanishi M, Ikehara Y, Nakanishi M, Ohnuma K, Chan T, Toyoda M, Akutsu H, Umezawa A, Asashima M, Hirabayashi J. Podocalyxin is a glycoprotein ligand of the human pluripotent stem cell-specific probe rBC2LCN. Stem Cells Transl Med 2013; 2:265-73. [PMID: 23526252 DOI: 10.5966/sctm.2012-0154] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
In comprehensive glycome analysis with a high-density lectin microarray, we have previously shown that the recombinant N-terminal domain of the lectin BC2L-C from Burkholderia cenocepacia (rBC2LCN) binds exclusively to undifferentiated human induced pluripotent stem (iPS) cells and embryonic stem (ES) cells but not to differentiated somatic cells. Here we demonstrate that podocalyxin, a heavily glycosylated type 1 transmembrane protein, is a glycoprotein ligand of rBC2LCN on human iPS cells and ES cells. When analyzed by DNA microarray, podocalyxin was found to be highly expressed in both iPS cells and ES cells. Western and lectin blotting revealed that rBC2LCN binds to podocalyxin with a high molecular weight of more than 240 kDa in undifferentiated iPS cells of six different origins and four ES cell lines, but no binding was observed in either differentiated mouse feeder cells or somatic cells. The specific binding of rBC2LCN to podocalyxin prepared from a large set of iPS cells (138 types) and ES cells (15 types) was also confirmed using a high-throughput antibody-overlay lectin microarray. Alkaline digestion greatly reduced the binding of rBC2LCN to podocalyxin, indicating that the major glycan ligands of rBC2LCN are presented on O-glycans. Furthermore, rBC2LCN was found to exhibit significant affinity to a branched O-glycan comprising an H type 3 structure (Ka, 2.5 × 10(4) M(-1)) prepared from human 201B7 iPS cells, indicating that H type 3 is a most probable potential pluripotency marker. We conclude that podocalyxin is a glycoprotein ligand of rBC2LCN on human iPS cells and ES cells.
Collapse
Affiliation(s)
- Hiroaki Tateno
- Research Center for Stem Cell Engineering, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|